 |
 |
Could this be it? Hadasit invests $3 million in CellCure The company has developed a stem cell treatment for Parkinson's disease. Batya Feldman 12 Mar 06 17:08 Biotechnology company CellCure Ltd has completed a financing round, in which it raised $3 million from Hadasit Bio Holdings Ltd. (TASE:HDST) , a subsidiary of Hadasit Medical Research Services and Development Ltd. (the technology transfer company of Hadassah Medical Organization). Founded in 2002, CellCure develops stem cell treatments for Parkinson's and other neurodegenerative diseases such as multiple sclerosis, ALS, Alzheimers and spinal disorders. Hadasit CEO Dr. Rafi Hofstein said, "The investment in CellCure, and in stem cell research and application, will ensure Hadassah's global advantage in cell therapy for Parkinson's." Hofstein added that the CellCure's cell therapy would be targeted at the US, where 300,000 new patients are diagnosed with Parkison's every year. 3 million people in the US currently suffer from Parkinson's and the market for treatments is estimated at $7.5 billion a year. The proceeds from the financing round will enable the company to continue development of solutions for Parkinson's and other neurodegenerative diseases. It will also enable the company to continue clinical trials with emphasis placed on cell preparation, in accordance with US Food and Drug Administration (FDA) rules which require cells of a quality for use in human beings, rather than replicating the results of animal trials. Published by Globes [online], Israel business news - www.globes.co.il - on March 12, 2006 Next article: Israelis' preferred Passover tourist destination - Far East ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn